Validation study of villous atrophy and small intestinal inflammation in Swedish biopsy registers

Department of Pediatrics, Orebro University Hospital, Orebro, Sweden.
BMC Gastroenterology (Impact Factor: 2.11). 02/2009; 9:19. DOI: 10.1186/1471-230X-9-19
Source: PubMed

ABSTRACT Small intestinal biopsy with villous atrophy (VA) is the gold standard for the diagnosis of celiac disease (CD). We validated VA (Marsh 3) and small intestinal inflammation without VA (Marsh 1+2) in Swedish regional biopsy registers.
All pathology departments in Sweden (n = 28) were searched to identify individuals with VA or duodenal/jejunal inflammation. The validation consisted of blinded examination of biopsy samples, manual review of biopsy reports, web surveys, and patient chart reviews of 121 individuals with VA and 39 with inflammation.
We identified 29,148 individuals with VA and 13,446 individuals with inflammation. In a blinded examination, Swedish pathologists correctly classified 90% of biopsies with VA. Manual screening of 1,534 biopsy reports (performed by co-author JFL and a research assistant) found that comorbidity other than CD was rare. IBD was the most common comorbidity and occurred in 0.3% of biopsies with VA (1.6% in inflammation). Among 114 patients with VA and available data, 108 (95%) had a clinical diagnosis of CD. 79% of the validated individuals with VA and 64% of those with inflammation had documented gastrointestinal symptoms prior to biopsy. 88% of the validated individuals with VA had positive CD serology before their first biopsy. 172/180 (96%) of Swedish gastroenterologists and 68/68 (100%) of pediatricians perform a small intestinal biopsy in at least 9 out of 10 individuals prior to diagnosis of CD.
Regional biopsy data are feasible to identify individuals with CD and small-intestinal inflammation. The specificity of CD is high in villous atrophy.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Nonalcoholic fatty liver disease is a common cause of chronic liver disease. Celiac disease alters intestinal permeability and treatment with a gluten-free diet often causes weight gain, but so far there are few reports of nonalcoholic fatty liver disease in patients with celiac disease. Population-based cohort study. We compared the risk of nonalcoholic fatty liver disease diagnosed from 1997-2009 in individuals with celiac disease (n=26,816) to matched reference individuals (n=130,051). Patients with any liver disease prior to celiac disease were excluded, as were individuals with a lifetime diagnosis of alcohol-related disorder to minimize misclassification of nonalcoholic fatty liver disease. Cox regression estimated hazard ratios for nonalcoholic fatty liver disease were determined. During 246,559 person-years of follow-up, 53 individuals with celiac disease had a diagnosis of nonalcoholic fatty liver disease (21/100,000 person-years). In comparison, we identified 85 reference individuals diagnosed with nonalcoholic fatty liver disease during 1,488,413 person-years (6/100,000 person-years). This corresponded to a hazard ratio of 2.8 (95%CI=2.0-3.8), with the highest risk estimates seen in children (HR=4.6; 95%CI=2.3-9.1). The risk increase in the first year after celiac disease diagnosis was 13.3 (95%CI=3.5-50.3) but remained significantly elevated even beyond 15 years after the diagnosis of celiac disease (HR=2.5; 95% CI 1.0-5.9). Individuals with celiac disease are at increased risk of nonalcoholic fatty liver disease compared to the general population. Excess risks were highest in the first year after celiac disease diagnosis, but persisted through 15 years beyond diagnosis with celiac disease. Copyright © 2015. Published by Elsevier B.V.
  • Alimentary Pharmacology & Therapeutics 11/2014; 40(10). DOI:10.1111/apt.12954 · 5.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Although poor sleep is common in numerous gastrointestinal diseases, data are scarce on the risk of poor sleep in celiac disease. The objective of this study was to estimate the risk of repeated use of hypnotics among individuals with celiac disease as a proxy measure for poor sleep.Methods This is a nationwide case¿control study including 2933 individuals with celiac disease and 14,571 matched controls from the general Swedish population. Poor sleep was defined as ¿2 prescriptions of hypnotics using prospective data from the National Prescribed Drug Register (data capture: July 2005-January 2008). We estimated odds ratios and hazard ratios for poor sleep before and after celiac disease diagnosis respectively.ResultsIn this study, poor sleep was seen in 129/2933 individuals (4.4%) with celiac disease, as compared with 487/14,571 controls (3.3%) (odds ratio¿=¿1.33; 95%CI¿=¿1.08-1.62). Data restricted to sleep complaints starting ¿1 year before celiac disease diagnosis revealed largely unchanged risk estimates (odds ratio¿=¿1.23; 95%CI¿=¿0.88-1.71) as compared with the overall risk (odds ratio 1.33). The risk of poor sleep in celiac disease was essentially not influenced by adjustment for concomitant psychiatric comorbidity (n¿=¿1744, adjusted odds ratio =1.26; 95%CI¿=¿1.02-1.54) or restless legs syndrome (n¿=¿108, adjusted odds ratio¿=¿1.33; 95%CI¿=¿1.08-1.63). Poor sleep was also more common after celiac disease diagnosis as compared with matched controls (hazard ratio¿=¿1.36; 95%CI¿=¿1.30-1.41).Conclusions In conclusion, individuals with celiac disease suffer an increased risk of poor sleep, both before and after diagnosis. Although we cannot rule out that surveillance bias has contributed to our findings, our results are consistent with previous data suggesting that sleep complaints may be a manifestation of celiac disease.
    BMC Gastroenterology 02/2015; 15(1):10. DOI:10.1186/s12876-015-0236-z · 2.11 Impact Factor

Full-text (2 Sources)

Available from
Jun 2, 2014